-
Cardiogenesis Corporation (OTCQB: CGCP), released comments regarding the STAR-heart study......
-
Three new analyses of subgroups from the SORT OUT III study presented at the European Society of Cardiology (ESC) meeting in Stockholm, Sweden, provide additional detail on longer-term follow-up subgroup safety and efficacy outcomes in the SORT OUT III trial in three high-risk subgroups (diabetes, acute coronary syndrome and multiple ...
-
A double-dose of the anti-clotting treatment clopidogrel, also known as Plavix, significantly reduces complications in heart patients undergoing angioplasty to clear blocked arteries. Shamir R. Mehta, an interventional cardiologist and associate professor of medicine of the Michael G......
-
MSD (known in the US and Canada as Merck) (NYSE:MRK) and Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to ...
-
As families return to the frenzied back-to-school pace, the American Heart Association is urging Hispanics to make time for the most important test they can take: a simple online health assessment to help them avoid heart disease and stroke......
-
Merck (known as MSD outside the United States and Canada) (NYSE:MRK) and Cardiome Pharma Corp......
-
InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market the LipiScan™ IVUS Coronary Imaging System......
-
Sibutramine, brand name Meridia is an appetite suppressant, a weight loss pill. Editors at the NEJM (New England Journal of Medicine) write it is difficult for them to discern a "credible rationale for keeping this medication on the market", even though it is restricted for people without heart disease......